74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ENANTA PHARMACEUTICALS INC
Closed
SectorHealthcare
5.65 1.07
Overview
Share price change
24h
Min
5.28
Max
5.65
Income | 94M -22M |
|---|---|
Sales | -51M 17M |
EPS | -1.05 |
Profit margin | -131.435 |
Employees | 131 |
EBITDA | -20M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +157.14% upside |
Next Earnings | 5 May 2025 |
|---|
Market Cap | 112M |
|---|---|
Previous open | 4.58 |
Previous close | 5.65 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
ENANTA PHARMACEUTICALS INC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ENANTA PHARMACEUTICALS INC Forecast
Price Target
By TipRanks
157.14% upside
12 Months Forecast
Average 14.4 USD 157.14%
High 21 USD
Low 5 USD
Based on 5 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
